Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 5Recruiting 4Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 12Gastrointestinal 5Genitourinary 4Breast 3Tumor-Agnostic 2Other solid neoplasm 2Head & Neck 2CNS 2Thoracic 1Sarcoma 1Dermatologic 1Classical hematology 1

Conditions

Neoplasms 2

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × niraparib × Tumor-Agnostic × Clear all
NCT01110603 2016-05-05

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Tesaro, Inc.

Phase 1 Terminated
12 enrolled
Tumor-Agnostic

Neoplasms

NCT01226901 2012-06-28

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Merck Sharp & Dohme LLC

Phase 1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡